The introduction of the drug in Australia is generating significant buzz within the healthcare community. This novel dual agonist – targeting both GLP-1 and GIP targets – presents a potentially effective option for https://australianpeptidestore.co/bpc-157-10mg-research-peptide-australian-peptide-store/